I neglected reporting about leukemia news at this year’s ASCO. One reason: Much of the news about advancing clinical studies for leukemia wasn’t timed for this event. Here are two important, positive examples of this:

Lorus to start late-stage trial of leukemia drug in H2
Mon Jun 14, 2010
* Says in talks with potential partners on the drug

The company, which is developing the drug, LOR-2040, for the treatment of acute myeloid leukemia, is currently in talks for a potential partnership on the drug, company spokesman Saeid Babaei told Reuters.

Read more by going to Reuters: LOR-2040 Trials To Start Soon.

Here is a second positive leukemia related post ASCO study:

Blinatumomab Study Shows Prolongued RFS
Drug Discovery & Development – June 15, 2010

Micromet, Inc. announced the presentation of updated results from a Phase 2 trial of the company’s lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL).

Results of the analysis demonstrate that a prolonged hematologic relapse free survival was observed in patients treated with blinatumomab. As of April 2010, six of nine evaluable, MRD responding, non-transplanted patients were in hematologic remission, ranging up to 23 months. Historical experience suggests that the majority of patients with MRD following front-line chemotherapy who do not receive a transplant will relapse within one year. Blinatumomab is the first of a new class of agents called BiTE antibodies, designed to harness the body’s T cells to kill cancer cells.

Go to Drug Study & Development/Leukemia to read the study and independent analysis.

Positive news on the leukemia front! Feel good and keep smiling! Pat

Leave a Reply